Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00786383 · ClinicalTrials.gov registry record · Phase 1
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00786383 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 25 participants.
The verdict
NCT00786383, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study. We believe that IMC-1121B blocks the growth factors made by the cancer cells, so new blood vessels do not grow. It is believed that without the new blood vessels, the cancer or tumor will not get the oxygen and food that it needs to grow. This may stop the cancer from growing or spreading and the tumor cells may die. Since normal blood vessels have already formed in adults, it might be possible to stop tumor growth without harming normal cells.
Interventions
- BIOLOGICAL IMC-1121B
- BIOLOGICAL 1121B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00786383
The ClinicalTrials.gov registry entry for NCT00786383 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IMC-1121B is the first listed.
NCT00786383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00786383 about?
NCT00786383 is a clinical study titled "Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy". We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study. We believe that IMC-1121B blocks the growth factors made by the cancer ce...
What is the current status of trial NCT00786383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2006-02. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00786383?
The interventions under investigation include: IMC-1121B (BIOLOGICAL), 1121B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00786383?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.